Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate
Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate
Lexicon Pharmaceuticals 2024 年第一季度每股收益爲 0.20 美元（0.20 美元），同上，銷售額爲 11.3 億美元，低於預期 14.01 萬美元
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 17.65 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $1.130 million which missed the analyst consensus estimate of $1.401 million by 19.33 percent. This is a 4.61K percent increase over sales of $24.000 thousand the same period last year.
Lexicon Pharmicals（納斯達克股票代碼：LXRX）公佈的季度虧損爲每股0.20美元，符合分析師的共識預期。這比去年同期每股虧損0.17美元（0.17美元）下降了17.65％。該公司公佈的季度銷售額爲11.30萬美元，比分析師普遍預期的14.01億美元低19.33％。與去年同期的24,000美元銷售額相比，增長了4.61萬個百分點。